British doctors lobby NHS to use cheap Avastin over Lucentis in AMD

Here's a new threat to Lucentis, the eye drug from Roche ($RHHBY) and Novartis ($NVS). British doctors are calling for the National Health Service to routinely use Roche's cancer med Avastin to treat patients with wet age-related macular degeneration, rather than the much costlier Lucentis. The two drugs work in a similar fashion and some studies show they work equally well for eye problems, but Avastin isn't licensed for use in the eye. Report

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Disorder: The Rare Disease Film Festival is back and bigger than ever, set for a West Coast debut with 50 films this fall.